FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281553838> ?p ?o ?g. }

• W4281553838 endingPage "616" @default.
• W4281553838 startingPage "611" @default.
• W4281553838 abstract "Purpose Long-term randomized data assessing the effect of ablative therapies in patients with oligometastases are lacking. The Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastases (SABR-COMET) randomized phase 2 trial was originally designed with 5 years of follow-up, but the trial was amended in 2016 to extend follow-up to 10 years. Herein we report oncologic outcomes beyond 5 years. Methods and Materials Patients were eligible if they had a controlled primary tumor and 1 to 5 metastases, with all metastases amenable to SABR. Patients were randomized in a 1:2 ratio between palliative standard-of-care treatment (control arm) versus SABR to all metastases plus standard of care (SABR arm). The primary endpoint was overall survival (OS) and secondary endpoints included progression-free survival (PFS), toxicity, quality of life (using the Functional Assessment of Cancer Therapy: General [FACT-G]), and time to new metastases. Results Ninety-nine patients were randomized between 2012 and 2016 (n = 33 in arm 1 vs n = 66 in arm 2). Primary tumor sites included lung (n = 18), breast (n = 18), colon (n = 18), prostate (n = 16), and other (n = 29). Eight-year OS was 27.2% in the SABR arm versus 13.6% in the control arm (hazard ratio, 0.50; 95% confidence interval, 0.30-0.84; P = .008). Eight-year PFS estimates were 21.3% versus 0.0%, respectively (hazard ratio, 0.45; 95% confidence interval, 0.28-0.72; P < .001). Rates of grade ≥ 2 acute or late toxic effects were 30.3% versus 9.1% (P = .019), with no new grade 3 to 5 toxic effects. FACT-G quality of life scores declined over time in both arms, but there were no differences in quality of life scores between arms. The use of systemic therapy overall was similar between arms, but patients in the SABR arm were less likely to require cytotoxic chemotherapy (33.3% vs 54.6%, respectively, P = .043). Conclusions SABR achieved durable improvements in OS and PFS, with no new major toxicity signals with extended follow-up. A minority of patients randomized to the SABR arm (21.3%) achieved > 5 years of survival without recurrence. Long-term randomized data assessing the effect of ablative therapies in patients with oligometastases are lacking. The Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastases (SABR-COMET) randomized phase 2 trial was originally designed with 5 years of follow-up, but the trial was amended in 2016 to extend follow-up to 10 years. Herein we report oncologic outcomes beyond 5 years. Patients were eligible if they had a controlled primary tumor and 1 to 5 metastases, with all metastases amenable to SABR. Patients were randomized in a 1:2 ratio between palliative standard-of-care treatment (control arm) versus SABR to all metastases plus standard of care (SABR arm). The primary endpoint was overall survival (OS) and secondary endpoints included progression-free survival (PFS), toxicity, quality of life (using the Functional Assessment of Cancer Therapy: General [FACT-G]), and time to new metastases. Ninety-nine patients were randomized between 2012 and 2016 (n = 33 in arm 1 vs n = 66 in arm 2). Primary tumor sites included lung (n = 18), breast (n = 18), colon (n = 18), prostate (n = 16), and other (n = 29). Eight-year OS was 27.2% in the SABR arm versus 13.6% in the control arm (hazard ratio, 0.50; 95% confidence interval, 0.30-0.84; P = .008). Eight-year PFS estimates were 21.3% versus 0.0%, respectively (hazard ratio, 0.45; 95% confidence interval, 0.28-0.72; P < .001). Rates of grade ≥ 2 acute or late toxic effects were 30.3% versus 9.1% (P = .019), with no new grade 3 to 5 toxic effects. FACT-G quality of life scores declined over time in both arms, but there were no differences in quality of life scores between arms. The use of systemic therapy overall was similar between arms, but patients in the SABR arm were less likely to require cytotoxic chemotherapy (33.3% vs 54.6%, respectively, P = .043). SABR achieved durable improvements in OS and PFS, with no new major toxicity signals with extended follow-up. A minority of patients randomized to the SABR arm (21.3%) achieved > 5 years of survival without recurrence." @default.
• W4281553838 created "2022-05-27" @default.
• W4281553838 creator A5007941548 @default.
• W4281553838 creator A5008861959 @default.
• W4281553838 creator A5012511065 @default.
• W4281553838 creator A5016085567 @default.
• W4281553838 creator A5019768466 @default.
• W4281553838 creator A5023270374 @default.
• W4281553838 creator A5030840846 @default.
• W4281553838 creator A5031508148 @default.
• W4281553838 creator A5032441898 @default.
• W4281553838 creator A5033401275 @default.
• W4281553838 creator A5033944759 @default.
• W4281553838 creator A5038486476 @default.
• W4281553838 creator A5039417225 @default.
• W4281553838 creator A5040003025 @default.
• W4281553838 creator A5043446527 @default.
• W4281553838 creator A5050537425 @default.
• W4281553838 creator A5055466353 @default.
• W4281553838 creator A5056712435 @default.
• W4281553838 creator A5057971434 @default.
• W4281553838 creator A5077453712 @default.
• W4281553838 creator A5084236214 @default.
• W4281553838 creator A5090288280 @default.
• W4281553838 date "2022-11-01" @default.
• W4281553838 modified "2023-10-17" @default.
• W4281553838 title "Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes" @default.
• W4281553838 cites W2131110909 @default.
• W4281553838 cites W2761351587 @default.
• W4281553838 cites W2775321189 @default.
• W4281553838 cites W2939770857 @default.
• W4281553838 cites W2944301866 @default.
• W4281553838 cites W2973470536 @default.
• W4281553838 cites W3032651552 @default.
• W4281553838 cites W3044423036 @default.
• W4281553838 cites W3107300149 @default.
• W4281553838 cites W3184091959 @default.
• W4281553838 cites W4232184817 @default.
• W4281553838 cites W4241696369 @default.
• W4281553838 doi "https://doi.org/10.1016/j.ijrobp.2022.05.004" @default.
• W4281553838 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35643253" @default.
• W4281553838 hasPublicationYear "2022" @default.
• W4281553838 type Work @default.
• W4281553838 citedByCount "63" @default.
• W4281553838 countsByYear W42815538382022 @default.
• W4281553838 countsByYear W42815538382023 @default.
• W4281553838 crossrefType "journal-article" @default.
• W4281553838 hasAuthorship W4281553838A5007941548 @default.
• W4281553838 hasAuthorship W4281553838A5008861959 @default.
• W4281553838 hasAuthorship W4281553838A5012511065 @default.
• W4281553838 hasAuthorship W4281553838A5016085567 @default.
• W4281553838 hasAuthorship W4281553838A5019768466 @default.
• W4281553838 hasAuthorship W4281553838A5023270374 @default.
• W4281553838 hasAuthorship W4281553838A5030840846 @default.
• W4281553838 hasAuthorship W4281553838A5031508148 @default.
• W4281553838 hasAuthorship W4281553838A5032441898 @default.
• W4281553838 hasAuthorship W4281553838A5033401275 @default.
• W4281553838 hasAuthorship W4281553838A5033944759 @default.
• W4281553838 hasAuthorship W4281553838A5038486476 @default.
• W4281553838 hasAuthorship W4281553838A5039417225 @default.
• W4281553838 hasAuthorship W4281553838A5040003025 @default.
• W4281553838 hasAuthorship W4281553838A5043446527 @default.
• W4281553838 hasAuthorship W4281553838A5050537425 @default.
• W4281553838 hasAuthorship W4281553838A5055466353 @default.
• W4281553838 hasAuthorship W4281553838A5056712435 @default.
• W4281553838 hasAuthorship W4281553838A5057971434 @default.
• W4281553838 hasAuthorship W4281553838A5077453712 @default.
• W4281553838 hasAuthorship W4281553838A5084236214 @default.
• W4281553838 hasAuthorship W4281553838A5090288280 @default.
• W4281553838 hasConcept C106159729 @default.
• W4281553838 hasConcept C126322002 @default.
• W4281553838 hasConcept C141071460 @default.
• W4281553838 hasConcept C143998085 @default.
• W4281553838 hasConcept C162324750 @default.
• W4281553838 hasConcept C168563851 @default.
• W4281553838 hasConcept C187625094 @default.
• W4281553838 hasConcept C203092338 @default.
• W4281553838 hasConcept C207103383 @default.
• W4281553838 hasConcept C44249647 @default.
• W4281553838 hasConcept C509974204 @default.
• W4281553838 hasConcept C71924100 @default.
• W4281553838 hasConcept C85393063 @default.
• W4281553838 hasConcept C91602232 @default.
• W4281553838 hasConceptScore W4281553838C106159729 @default.
• W4281553838 hasConceptScore W4281553838C126322002 @default.
• W4281553838 hasConceptScore W4281553838C141071460 @default.
• W4281553838 hasConceptScore W4281553838C143998085 @default.
• W4281553838 hasConceptScore W4281553838C162324750 @default.
• W4281553838 hasConceptScore W4281553838C168563851 @default.
• W4281553838 hasConceptScore W4281553838C187625094 @default.
• W4281553838 hasConceptScore W4281553838C203092338 @default.
• W4281553838 hasConceptScore W4281553838C207103383 @default.
• W4281553838 hasConceptScore W4281553838C44249647 @default.
• W4281553838 hasConceptScore W4281553838C509974204 @default.
• W4281553838 hasConceptScore W4281553838C71924100 @default.
• W4281553838 hasConceptScore W4281553838C85393063 @default.
• W4281553838 hasConceptScore W4281553838C91602232 @default.
• W4281553838 hasIssue "4" @default.

• next